Earlier, Serra et al. (Hu et al., 2021b) discovered that using ErbB-2 inhibitors or MEK inhibitors in conjunction with PI3K inhibitors enhances the efficacy of the treatment, leading to reduced proliferation of breast cancer and improved anti-cancer effects compared to monotherapy. Here, MAP2K7 is linked to cancer.